daunorubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics, daunorubicin derivatives	786	20830-81-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: daunorubicin acetyladriamycin cerubidin daunoblastina daunomycine daunorubicine Leukaemomycin C rubidomycin daunorubicin hydrochloride daunorubicin citrate daunorubicin HCl	A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Molecular weight: 527.53 Formula: C27H29NO10 CLOGP: 0.78 LIPINSKI: 2 HAC: 11 HDO: 5 TPSA: 185.84 ALOGS: -2.93 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

daunorubicin
acetyladriamycin
cerubidin
daunoblastina
daunomycine
daunorubicine
Leukaemomycin C
rubidomycin
daunorubicin hydrochloride
daunorubicin citrate
daunorubicin HCl

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.

Molecular weight: 527.53
Formula: C27H29NO10
CLOGP: 0.78
LIPINSKI: 2
HAC: 11
HDO: 5
TPSA: 185.84
ALOGS: -2.93
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.04 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.05 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	32.05 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	47.57 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	14.24 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 19, 1979	FDA
Feb. 24, 2021	PMDA	Meiji Seika Pharma Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	673.79	24.68	342	9416	97325	50498041
Hypofibrinogenaemia	364.80	24.68	75	9683	1037	50594329
Sepsis	161.43	24.68	161	9597	132764	50462602
Posterior reversible encephalopathy syndrome	159.70	24.68	71	9687	14857	50580509
Hyperbilirubinaemia	140.53	24.68	57	9701	9513	50585853
Neutropenia	126.57	24.68	149	9609	147816	50447550
Bone marrow failure	113.27	24.68	69	9689	27555	50567811
Mucormycosis	111.47	24.68	34	9724	2449	50592917
Pneumatosis intestinalis	108.24	24.68	32	9726	2071	50593295
Febrile bone marrow aplasia	104.51	24.68	41	9717	6270	50589096
Colitis	101.46	24.68	73	9685	38456	50556910
Second primary malignancy	94.07	24.68	39	9719	6875	50588491
Septic shock	93.82	24.68	82	9676	57093	50538273
Human bocavirus infection	92.49	24.68	20	9738	356	50595010
Clostridium difficile colitis	90.33	24.68	51	9707	17691	50577675
Haematotoxicity	89.08	24.68	39	9719	7856	50587510
Thrombocytopenia	85.76	24.68	114	9644	127559	50467807
Cardiotoxicity	83.49	24.68	36	9722	6991	50588375
Secondary immunodeficiency	83.27	24.68	23	9735	1165	50594201
Human herpesvirus 6 infection	81.11	24.68	27	9731	2579	50592787
Herpes simplex	79.58	24.68	35	9723	7127	50588239
Blood culture positive	74.90	24.68	29	9729	4279	50591087
Enterobacter infection	72.75	24.68	23	9735	1865	50593501
Bronchopulmonary aspergillosis	71.32	24.68	33	9725	7559	50587807
Aplasia	71.06	24.68	27	9731	3786	50591580
Neutropenic colitis	67.17	24.68	23	9735	2394	50592972
Venoocclusive disease	60.42	24.68	20	9738	1876	50593490
Ejection fraction decreased	60.28	24.68	40	9718	18480	50576886
Left atrial hypertrophy	59.46	24.68	10	9748	40	50595326
Cerebral venous sinus thrombosis	58.84	24.68	19	9739	1649	50593717
Mucosal inflammation	58.75	24.68	54	9704	40088	50555278
Fatigue	58.60	24.68	32	9726	707569	49887797
Disseminated intravascular coagulation	58.18	24.68	38	9720	17097	50578269
Arthralgia	58.03	24.68	8	9750	438694	50156672
Gastroenteritis norovirus	57.97	24.68	19	9739	1728	50593638
Multiple organ dysfunction syndrome	55.51	24.68	58	9700	50279	50545087
Bacterial infection	55.02	24.68	36	9722	16245	50579121
Pancytopenia	54.77	24.68	74	9684	83956	50511410
Haemophagocytic lymphohistiocytosis	52.73	24.68	28	9730	8605	50586761
Pneumonia fungal	50.88	24.68	22	9736	4298	50591068
Tumour lysis syndrome	50.86	24.68	26	9732	7395	50587971
Venous thrombosis	50.18	24.68	22	9736	4444	50590922
Aspergillus infection	49.97	24.68	25	9733	6796	50588570
Pain	49.61	24.68	25	9733	578878	50016488
Angiokeratoma	49.11	24.68	10	9748	131	50595235
Rhinovirus infection	48.29	24.68	20	9738	3514	50591852
Pyrexia	45.93	24.68	169	9589	380034	50215332
Acute myeloid leukaemia recurrent	45.65	24.68	15	9743	1375	50593991
Pneumonia moraxella	45.32	24.68	8	9750	45	50595321
Cerebral venous thrombosis	45.05	24.68	16	9742	1855	50593511
Hepatic failure	44.47	24.68	42	9716	32241	50563125
Electrocardiogram PR shortened	44.15	24.68	10	9748	222	50595144
Stenotrophomonas infection	42.96	24.68	15	9743	1654	50593712
Neutropenic sepsis	42.31	24.68	29	9729	14118	50581248
Pulse waveform abnormal	42.03	24.68	8	9750	72	50595294
Ankle brachial index decreased	41.93	24.68	8	9750	73	50595293
Bacteraemia	41.79	24.68	29	9729	14404	50580962
Carotid intima-media thickness increased	41.54	24.68	8	9750	77	50595289
Venoocclusive liver disease	41.52	24.68	19	9739	4242	50591124
Neoplasm recurrence	41.37	24.68	16	9742	2353	50593013
Enterococcal infection	41.08	24.68	22	9736	6876	50588490
Enteritis	40.79	24.68	22	9736	6973	50588393
Staphylococcal sepsis	40.67	24.68	22	9736	7014	50588352
Acute lymphocytic leukaemia recurrent	40.49	24.68	15	9743	1960	50593406
Respiratory failure	39.01	24.68	66	9692	91115	50504251
Blood bilirubin increased	37.26	24.68	38	9720	32000	50563366
Streptococcal bacteraemia	37.13	24.68	13	9745	1445	50593921
Bone marrow disorder	37.04	24.68	14	9744	1934	50593432
Alanine aminotransferase increased	36.53	24.68	63	9695	88296	50507070
Blast crisis in myelogenous leukaemia	36.28	24.68	10	9748	502	50594864
Otitis externa	36.27	24.68	13	9745	1547	50593819
Tachycardia	34.72	24.68	66	9692	99697	50495669
Neurotoxicity	34.42	24.68	26	9732	14714	50580652
Malaise	34.36	24.68	11	9747	335521	50259845
Chronic myeloid leukaemia recurrent	34.18	24.68	8	9750	206	50595160
Acute myeloid leukaemia	33.90	24.68	26	9732	15048	50580318
Minimal residual disease	32.84	24.68	7	9751	116	50595250
Aborted pregnancy	32.61	24.68	6	9752	44	50595322
Leukaemia recurrent	31.24	24.68	11	9747	1243	50594123
Pleural effusion	30.98	24.68	56	9702	81398	50513968
Fall	30.88	24.68	13	9745	334919	50260447
Hepatocellular injury	30.58	24.68	31	9727	25916	50569450
Differentiation syndrome	30.36	24.68	10	9748	923	50594443
Leukopenia	30.36	24.68	50	9708	67478	50527888
Left ventricular dysfunction	30.15	24.68	21	9737	10485	50584881
Genotoxicity	29.73	24.68	5	9753	20	50595346
Dysplasia	29.05	24.68	9	9749	682	50594684
Device related infection	28.60	24.68	27	9731	20708	50574658
Breakthrough pain	28.41	24.68	10	9748	1129	50594237
Leukoerythroblastosis	28.24	24.68	7	9751	231	50595135
Metastases to pancreas	28.21	24.68	7	9751	232	50595134
Respiratory distress	28.13	24.68	32	9726	30457	50564909
Dyspnoea	27.98	24.68	39	9719	547569	50047797
Geotrichum infection	27.94	24.68	8	9750	462	50594904
Trichosporon infection	27.90	24.68	7	9751	243	50595123
Cholestasis	27.50	24.68	29	9729	25372	50569994
Ileus paralytic	27.20	24.68	14	9744	4036	50591330
Ureaplasma infection	27.17	24.68	8	9750	510	50594856
Abdominal discomfort	26.70	24.68	6	9752	231635	50363731
Nausea	26.39	24.68	61	9697	705337	49890029
Lung opacity	26.39	24.68	11	9747	1962	50593404
Hypotension	26.12	24.68	102	9656	235367	50359999
Pseudomonas test positive	25.21	24.68	8	9750	656	50594710
Hyperglycaemia	25.13	24.68	33	9725	36372	50558994
Escherichia infection	24.88	24.68	19	9739	10922	50584444

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	506.62	20.65	390	11322	111850	29450965
Hypofibrinogenaemia	327.82	20.65	83	11629	1418	29561397
Posterior reversible encephalopathy syndrome	191.85	20.65	86	11626	8890	29553925
Aspergillus infection	157.43	20.65	79	11633	10502	29552313
Neutropenia	155.88	20.65	224	11488	131487	29431328
Septic shock	143.76	20.65	149	11563	62411	29500404
Bone marrow failure	130.90	20.65	99	11613	27350	29535465
Sepsis	127.21	20.65	213	11499	142469	29420346
Multiple-drug resistance	122.04	20.65	49	11663	3851	29558964
Hyperbilirubinaemia	121.63	20.65	75	11637	14859	29547956
Haematotoxicity	120.62	20.65	57	11655	6642	29556173
Mucormycosis	112.03	20.65	50	11662	5108	29557707
Hypertriglyceridaemia	108.79	20.65	55	11657	7420	29555395
Bronchopulmonary aspergillosis	105.65	20.65	64	11648	12280	29550535
Acute myeloid leukaemia recurrent	98.54	20.65	34	11678	1746	29561069
Leukaemia recurrent	77.08	20.65	27	11685	1450	29561365
Pancytopenia	72.35	20.65	123	11589	83045	29479770
Neutropenic colitis	70.98	20.65	29	11683	2382	29560433
Colitis	70.88	20.65	74	11638	31174	29531641
Acute lymphocytic leukaemia recurrent	69.79	20.65	29	11683	2487	29560328
Multiple organ dysfunction syndrome	68.11	20.65	103	11609	63013	29499802
Hepatotoxicity	67.03	20.65	56	11656	17811	29545004
Pyrexia	64.46	20.65	254	11458	287368	29275447
Cerebral venous thrombosis	63.35	20.65	19	11693	619	29562196
Venoocclusive disease	62.87	20.65	27	11685	2512	29560303
Glioma	62.52	20.65	16	11696	285	29562530
Blood fibrinogen decreased	60.53	20.65	20	11692	898	29561917
Pneumonia fungal	60.09	20.65	34	11678	5743	29557072
Fungal infection	60.02	20.65	47	11665	13638	29549177
Osteonecrosis	58.36	20.65	46	11666	13473	29549342
Febrile bone marrow aplasia	57.50	20.65	36	11676	7315	29555500
Tumour lysis syndrome	57.28	20.65	46	11666	13838	29548977
Bacteraemia	56.79	20.65	49	11663	16274	29546541
Central nervous system fungal infection	55.80	20.65	15	11697	326	29562489
Myelosuppression	51.48	20.65	41	11671	12186	29550629
Glioblastoma multiforme	49.70	20.65	16	11696	661	29562154
Fatigue	47.43	20.65	34	11678	316787	29246028
Blood bilirubin increased	41.87	20.65	59	11653	33834	29528981
Death	41.23	20.65	45	11667	342039	29220776
Oesophageal stenosis	40.25	20.65	17	11695	1518	29561297
Cerebral venous sinus thrombosis	40.04	20.65	12	11700	390	29562425
Neoplasm recurrence	39.23	20.65	18	11694	1959	29560856
Mucosal inflammation	37.55	20.65	54	11658	31541	29531274
Large intestine infection	35.94	20.65	15	11697	1300	29561515
Lower respiratory tract infection fungal	35.73	20.65	12	11700	567	29562248
Candida infection	34.40	20.65	36	11676	15189	29547626
Congenital pneumonia	34.35	20.65	8	11704	94	29562721
Personality change due to a general medical condition	34.24	20.65	7	11705	42	29562773
Candida endophthalmitis	33.68	20.65	8	11704	103	29562712
Device related infection	33.60	20.65	36	11676	15600	29547215
Haemophagocytic lymphohistiocytosis	33.46	20.65	30	11682	10474	29552341
Respiratory failure	33.21	20.65	99	11613	97032	29465783
Acute monocytic leukaemia	33.10	20.65	10	11702	334	29562481
Disseminated intravascular coagulation	32.77	20.65	40	11672	19940	29542875
Intussusception	32.72	20.65	11	11701	521	29562294
Systemic mycosis	32.55	20.65	14	11698	1307	29561508
Gallbladder empyema	32.49	20.65	7	11705	56	29562759
Inappropriate antidiuretic hormone secretion	32.43	20.65	30	11682	10902	29551913
Hypoxia	32.16	20.65	63	11649	47316	29515499
Meningeal neoplasm	32.06	20.65	7	11705	60	29562755
Arthralgia	31.92	20.65	8	11704	139609	29423206
Dizziness	31.54	20.65	18	11694	189666	29373149
Leukoencephalopathy	30.85	20.65	19	11693	3748	29559067
Skin toxicity	30.83	20.65	19	11693	3752	29559063
Pseudomonas test positive	30.60	20.65	12	11700	885	29561930
Myocardial infarction	30.18	20.65	4	11708	110292	29452523
Aplasia	29.53	20.65	19	11693	4044	29558771
Clostridium difficile colitis	29.42	20.65	31	11681	13181	29549634
Differentiation syndrome	28.10	20.65	12	11700	1101	29561714
Systemic candida	27.93	20.65	16	11696	2764	29560051
Brain sarcoma	27.77	20.65	5	11707	13	29562802
Pain	27.46	20.65	17	11695	171415	29391400
Malaise	26.73	20.65	15	11697	159587	29403228
Hepatic steatosis	26.28	20.65	31	11681	14915	29547900
Stomatitis	25.97	20.65	50	11662	37063	29525752
Thymus hypoplasia	25.70	20.65	7	11705	160	29562655
Lymphoid tissue hypoplasia	25.70	20.65	7	11705	160	29562655
Product use in unapproved indication	25.49	20.65	84	11628	86791	29476024
Non-alcoholic steatohepatitis	24.84	20.65	10	11702	790	29562025
Prothrombin level abnormal	24.66	20.65	6	11706	86	29562729
Thrombocytopenia	24.51	20.65	112	11600	134711	29428104
Hip deformity	24.05	20.65	6	11706	96	29562719
Myocardial oedema	23.89	20.65	7	11705	210	29562605
Nervous system disorder	23.47	20.65	27	11685	12647	29550168
Vascular access complication	23.46	20.65	7	11705	224	29562591
Disseminated aspergillosis	23.14	20.65	8	11704	413	29562402
Drug resistance	22.97	20.65	35	11677	21505	29541310
Enamel anomaly	22.84	20.65	6	11706	119	29562696
Cerebellar tumour	22.78	20.65	5	11707	44	29562771
Renal replacement therapy	22.68	20.65	5	11707	45	29562770
Leukopenia	22.50	20.65	60	11652	55143	29507672
Superior sagittal sinus thrombosis	22.46	20.65	7	11705	260	29562555
Intracranial pressure increased	22.18	20.65	15	11697	3470	29559345
Infection reactivation	21.89	20.65	10	11702	1077	29561738
Coagulopathy	21.84	20.65	31	11681	17876	29544939
Rash	21.67	20.65	26	11686	189793	29373022
Overdose	21.58	20.65	3	11709	79816	29482999
Intracranial tumour haemorrhage	21.54	20.65	7	11705	298	29562517
Weight decreased	21.47	20.65	17	11695	150888	29411927
Enterococcal infection	21.32	20.65	21	11691	8247	29554568
Recurrent cancer	21.23	20.65	10	11702	1155	29561660
Second primary malignancy	21.06	20.65	19	11693	6686	29556129
Asthenia	21.04	20.65	33	11679	215217	29347598
Hypoalbuminaemia	20.87	20.65	23	11689	10282	29552533

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1074.13	20.08	701	20503	186956	64290572
Hypofibrinogenaemia	379.26	20.08	93	21111	1685	64475843
Posterior reversible encephalopathy syndrome	330.70	20.08	158	21046	22788	64454740
Aspergillus infection	289.67	20.08	130	21074	16249	64461279
Secondary immunodeficiency	289.45	20.08	82	21122	2642	64474886
Neutropenia	263.09	20.08	357	20847	239267	64238261
Bone marrow failure	262.60	20.08	175	21029	47777	64429751
Sepsis	260.22	20.08	348	20856	229993	64247535
Bronchopulmonary aspergillosis	240.71	20.08	120	21084	18965	64458563
Septic shock	212.80	20.08	215	20989	105222	64372306
Bacterial infection	207.78	20.08	119	21085	24831	64452697
Haematotoxicity	201.72	20.08	94	21110	12802	64464726
Hyperbilirubinaemia	181.56	20.08	103	21101	21102	64456426
Mycobacterium chelonae infection	172.59	20.08	52	21152	2085	64475443
Clostridium difficile colitis	167.67	20.08	107	21097	27116	64450412
Mucormycosis	164.88	20.08	69	21135	7272	64470256
Colitis	145.33	20.08	134	21070	58540	64418988
Pseudomonal sepsis	144.97	20.08	57	21147	5115	64472413
Acute myeloid leukaemia recurrent	139.09	20.08	47	21157	2737	64474791
Parainfluenzae virus infection	128.49	20.08	51	21153	4692	64472836
Neutropenic colitis	126.69	20.08	50	21154	4531	64472997
Multiple-drug resistance	125.83	20.08	55	21149	6447	64471081
Febrile bone marrow aplasia	125.08	20.08	65	21139	11190	64466338
Human herpesvirus 6 infection	118.99	20.08	48	21156	4606	64472922
Pancytopenia	114.24	20.08	184	21020	143125	64334403
Pneumonia fungal	112.43	20.08	56	21148	8821	64468707
Human bocavirus infection	112.35	20.08	28	21176	543	64476985
Hypertriglyceridaemia	111.19	20.08	60	21144	11145	64466383
Acute lymphocytic leukaemia recurrent	104.57	20.08	42	21162	3984	64473544
Pyrexia	101.72	20.08	407	20797	558237	63919291
Venoocclusive disease	101.53	20.08	41	21163	3944	64473584
Second primary malignancy	100.42	20.08	58	21146	12279	64465249
Multiple organ dysfunction syndrome	100.31	20.08	144	21060	101269	64376259
Leukaemia recurrent	99.62	20.08	36	21168	2558	64474970
Fatigue	99.47	20.08	62	21142	748668	63728860
Fungal infection	98.21	20.08	85	21119	34166	64443362
Thymus hypoplasia	94.26	20.08	24	21180	509	64477019
Pain	93.15	20.08	33	21171	553478	63924050
Arthralgia	92.30	20.08	17	21187	442243	64035285
Disseminated intravascular coagulation	92.18	20.08	80	21124	32268	64445260
Bacteraemia	92.12	20.08	74	21130	26837	64450691
Pneumatosis intestinalis	90.80	20.08	41	21163	5188	64472340
Tumour lysis syndrome	89.93	20.08	64	21140	19376	64458152
Mucosal inflammation	86.88	20.08	105	21099	62479	64415049
Thrombocytopenia	85.32	20.08	211	20993	223590	64253938
Cerebral venous sinus thrombosis	83.62	20.08	29	21175	1826	64475702
Neoplasm recurrence	83.47	20.08	35	21169	3704	64473824
Aplasia	82.58	20.08	42	21162	6911	64470617
Lymphoid tissue hypoplasia	81.41	20.08	21	21183	470	64477058
Cytomegalovirus viraemia	77.89	20.08	47	21157	10781	64466747
Glioma	74.67	20.08	20	21184	520	64477008
Abscess bacterial	72.29	20.08	21	21183	740	64476788
Haemophagocytic lymphohistiocytosis	70.20	20.08	53	21151	17556	64459972
Hepatotoxicity	68.88	20.08	75	21129	39887	64437641
Diffuse alveolar damage	67.95	20.08	29	21175	3206	64474322
Malaise	67.66	20.08	23	21181	396224	64081304
Enterobacter infection	67.43	20.08	30	21174	3666	64473862
Blood culture positive	66.73	20.08	38	21166	7830	64469698
Viral infection	66.11	20.08	70	21134	36070	64441458
Enteritis	65.84	20.08	44	21160	12033	64465495
Cardiotoxicity	64.76	20.08	41	21163	10233	64467295
Respiratory failure	63.53	20.08	154	21050	161029	64316499
Oesophageal candidiasis	63.41	20.08	37	21167	7980	64469548
Ejection fraction decreased	62.34	20.08	61	21143	28646	64448882
Cerebral venous thrombosis	61.79	20.08	25	21179	2416	64475112
Myelosuppression	60.07	20.08	55	21149	23775	64453753
Dizziness	56.43	20.08	36	21168	430127	64047401
Cytomegalovirus chorioretinitis	56.39	20.08	29	21175	4883	64472645
Coronavirus infection	55.94	20.08	30	21174	5500	64472028
Glioblastoma multiforme	55.91	20.08	19	21185	1125	64476403
Rhinovirus infection	55.64	20.08	31	21173	6125	64471403
Cystitis bacterial	55.36	20.08	15	21189	408	64477120
Differentiation syndrome	55.33	20.08	22	21182	2032	64475496
Blood fibrinogen decreased	55.11	20.08	20	21184	1438	64476090
Blood bilirubin increased	54.35	20.08	80	21124	57473	64420055
Device related infection	53.68	20.08	58	21146	30568	64446960
Left atrial hypertrophy	52.31	20.08	10	21194	50	64477478
Acute myeloid leukaemia	51.66	20.08	54	21150	27409	64450119
Drug hypersensitivity	49.84	20.08	9	21195	237806	64239722
Pseudomonas test positive	49.82	20.08	19	21185	1569	64475959
Norovirus test positive	49.82	20.08	14	21190	437	64477091
Enterococcal infection	49.30	20.08	39	21165	13827	64463701
Viraemia	49.15	20.08	21	21183	2328	64475200
Candida infection	49.04	20.08	56	21148	31363	64446165
Osteonecrosis	48.67	20.08	53	21151	28176	64449352
Staphylococcal sepsis	47.42	20.08	37	21167	12862	64464666
Dyspnoea	46.52	20.08	105	21099	718569	63758959
Fusarium infection	46.47	20.08	18	21186	1551	64475977
Minimal residual disease	46.32	20.08	13	21191	404	64477124
Inappropriate antidiuretic hormone secretion	45.87	20.08	46	21158	22243	64455285
Fall	45.58	20.08	42	21162	416784	64060744
Lower respiratory tract infection fungal	44.94	20.08	15	21189	840	64476688
Hypoxia	44.52	20.08	93	21111	88056	64389472
Leukopenia	44.51	20.08	101	21103	101141	64376387
Disseminated aspergillosis	44.39	20.08	14	21190	654	64476874
Ileus paralytic	44.29	20.08	30	21174	8385	64469143
Nausea	43.01	20.08	125	21079	785675	63691853
Renal replacement therapy	42.85	20.08	10	21194	145	64477383
Systemic mycosis	42.84	20.08	19	21185	2304	64475224
Respiratory distress	42.72	20.08	68	21136	52263	64425265
Carotid intima-media thickness increased	42.20	20.08	9	21195	84	64477444
Pruritus	41.12	20.08	26	21178	312374	64165154
Geotrichum infection	40.03	20.08	14	21190	904	64476624
Angiokeratoma	39.14	20.08	10	21194	215	64477313
Weight decreased	38.69	20.08	23	21181	285716	64191812
Depression	38.26	20.08	7	21197	183284	64294244
Herpes simplex	38.25	20.08	30	21174	10506	64467022
Pneumonia moraxella	38.07	20.08	8	21196	69	64477459
Stenotrophomonas infection	37.73	20.08	19	21185	3061	64474467
Ankle brachial index decreased	37.67	20.08	8	21196	73	64477455
Encephalitis	37.65	20.08	32	21172	12539	64464989
Large intestine infection	37.53	20.08	18	21186	2610	64474918
Pulse waveform abnormal	37.48	20.08	8	21196	75	64477453
Electrocardiogram PR shortened	37.26	20.08	10	21194	262	64477266
Central nervous system fungal infection	37.25	20.08	11	21193	411	64477117
Acute monocytic leukaemia	36.72	20.08	11	21193	432	64477096
Oesophageal stenosis	36.55	20.08	20	21184	3814	64473714
Pulmonary haemorrhage	36.48	20.08	32	21172	13077	64464451
Neurotoxicity	36.42	20.08	45	21159	27359	64450169
Abdominal discomfort	35.89	20.08	8	21196	182314	64295214
Peripheral swelling	35.89	20.08	12	21192	209141	64268387
Bacterial sepsis	35.52	20.08	25	21179	7432	64470096
Systemic candida	35.43	20.08	22	21182	5307	64472221
Acute respiratory distress syndrome	35.14	20.08	53	21151	38882	64438646
Pseudomonas infection	35.14	20.08	36	21168	17847	64459681
Infusion related reaction	34.93	20.08	6	21198	164461	64313067
Leukoencephalopathy	34.69	20.08	24	21180	6943	64470585
Insomnia	34.56	20.08	11	21193	197825	64279703
Myocardial infarction	33.20	20.08	7	21197	165814	64311714
Venoocclusive liver disease	33.12	20.08	27	21177	9988	64467540
Product use in unapproved indication	32.97	20.08	130	21074	176488	64301040
Escherichia infection	32.49	20.08	32	21172	15136	64462392
Antithrombin III decreased	32.49	20.08	10	21194	431	64477097
Intracranial pressure increased	32.29	20.08	23	21181	6966	64470562
Neutropenic sepsis	32.20	20.08	39	21165	23233	64454295
Urticaria	32.12	20.08	5	21199	147312	64330216
Candida endophthalmitis	32.10	20.08	8	21196	155	64477373
Pleural effusion	32.06	20.08	103	21101	126456	64351072
Hepatic steatosis	32.04	20.08	45	21159	30962	64446566
Venous thrombosis	31.81	20.08	22	21182	6359	64471169
Superior sagittal sinus thrombosis	31.78	20.08	12	21192	964	64476564
Alanine aminotransferase increased	31.53	20.08	109	21095	138922	64338606
Overdose	31.41	20.08	7	21197	159559	64317969
Skin toxicity	31.13	20.08	22	21182	6580	64470948
Gastroenteritis norovirus	30.75	20.08	16	21188	2759	64474769
Gallbladder empyema	30.63	20.08	7	21197	92	64477436
Muscle spasms	30.27	20.08	5	21199	141018	64336510
Blast crisis in myelogenous leukaemia	30.21	20.08	11	21193	798	64476730
Pulmonary mucormycosis	30.17	20.08	11	21193	801	64476727
Pancreatitis acute	30.03	20.08	52	21152	42803	64434725
Left ventricular dysfunction	29.52	20.08	32	21172	16922	64460606
Tachycardia	29.46	20.08	112	21092	149467	64328061
Aborted pregnancy	29.42	20.08	6	21198	44	64477484
Hypersensitivity	29.24	20.08	14	21190	196438	64281090
Intussusception	28.92	20.08	11	21193	902	64476626
Brain sarcoma	28.70	20.08	5	21199	13	64477515
Swelling	27.82	20.08	9	21195	160209	64317319
Bone marrow disorder	27.66	20.08	15	21189	2810	64474718
Chronic myeloid leukaemia recurrent	27.65	20.08	8	21196	278	64477250
Personality change due to a general medical condition	27.56	20.08	7	21197	147	64477381
Diarrhoea	27.10	20.08	134	21070	722570	63754958
Hypoalbuminaemia	26.73	20.08	31	21173	17643	64459885
Cytomegalovirus infection reactivation	26.73	20.08	19	21185	5737	64471791
Lung opacity	25.92	20.08	15	21189	3184	64474344
Myalgia	25.67	20.08	10	21194	158607	64318921
Escherichia bacteraemia	25.47	20.08	18	21186	5385	64472143
Myelopathy	25.40	20.08	16	21188	3958	64473570
Neoplasm progression	25.24	20.08	47	21157	40917	64436611
Toxicity to various agents	25.19	20.08	51	21153	363462	64114066
Musculoskeletal stiffness	25.07	20.08	5	21199	123201	64354327
Rash	24.96	20.08	73	21131	458476	64019052
Lymphopenia	24.69	20.08	36	21168	25621	64451907
Blood pressure increased	24.62	20.08	13	21191	172539	64304989
Genotoxicity	24.59	20.08	5	21199	36	64477492
Leukoerythroblastosis	24.09	20.08	7	21197	247	64477281
Coagulopathy	24.04	20.08	40	21164	31880	64445648
Streptococcal bacteraemia	23.84	20.08	14	21190	3053	64474475
Non-alcoholic steatohepatitis	23.79	20.08	12	21192	1940	64475588
Graft versus host disease in skin	23.34	20.08	17	21187	5330	64472198
Escherichia sepsis	23.03	20.08	19	21185	7146	64470382
Fungal sepsis	22.60	20.08	11	21193	1647	64475881
Contusion	22.42	20.08	5	21199	113960	64363568
T-cell type acute leukaemia	22.33	20.08	6	21198	158	64477370
Pain in extremity	22.31	20.08	41	21163	303044	64174484
Escherichia test positive	22.24	20.08	13	21191	2812	64474716
Alpha haemolytic streptococcal infection	22.19	20.08	11	21193	1714	64475814
Back pain	22.05	20.08	30	21174	250141	64227387
Myocardial oedema	21.99	20.08	7	21197	337	64477191
Asthenia	21.96	20.08	70	21134	427974	64049554
Gait disturbance	21.72	20.08	15	21189	172140	64305388
Staphylococcal infection	21.64	20.08	50	21154	50628	64426900
Peripheral motor neuropathy	21.64	20.08	13	21191	2957	64474571
Cerebellar tumour	21.39	20.08	5	21199	73	64477455
Pancreatitis	21.39	20.08	55	21149	59552	64417976
Cerebral ischaemia	21.31	20.08	21	21183	9941	64467587
Hip deformity	21.27	20.08	6	21198	190	64477338
Atypical pneumonia	21.24	20.08	16	21188	5278	64472250
Appendicitis	20.86	20.08	24	21180	13545	64463983
Graft versus host disease	20.51	20.08	24	21180	13789	64463739
Infection reactivation	20.50	20.08	11	21193	2019	64475509
Weight increased	20.45	20.08	24	21180	213324	64264204
Cerebral haemorrhage	20.28	20.08	49	21155	51041	64426487
Ureaplasma infection	20.21	20.08	8	21196	730	64476798
Dehydration	20.13	20.08	25	21179	216738	64260790
Overgrowth fungal	20.11	20.08	5	21199	96	64477432

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DB02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances
ATC	L01XY01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Combinations of antineoplastic agents
FDA CS	M0028312	Anthracyclines
FDA MoA	N0000000176	Topoisomerase Inhibitors
FDA EPC	N0000175414	Anthracycline Topoisomerase Inhibitor
MeSH PA	D000903	Antibiotics, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D059005	Topoisomerase II Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute lymphoid leukemia	indication	91857003	DOID:9952
Acute myeloid leukemia, disease	indication	91861009
Erythroleukemia, FAB M6	indication	93451002
Kaposi's sarcoma	indication	109385007
Acute promyelocytic leukemia, FAB M3	indication	110004001
Acute monocytic/monoblastic leukemia	indication	413442004
Blast crisis of chronic myeloidleukemia	indication	413656006
Nephroblastoma	off-label use	302849000	DOID:2154
Neuroblastoma	off-label use	432328008	DOID:769
Mycosis	contraindication	3218000	DOID:1564
Pericarditis	contraindication	3238004	DOID:1787
Ventricular tachycardia	contraindication	25569003
Viral disease	contraindication	34014006	DOID:934
Hyperuricemia	contraindication	35885006	DOID:1920
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Myocarditis	contraindication	50920009	DOID:820
Epilepsy	contraindication	84757009	DOID:1826
Cardiomyopathy	contraindication	85898001	DOID:0050700
Bacterial infectious disease	contraindication	87628006
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001
Granulocytopenic disorder	contraindication	417672002
Protozoal Infection	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.85	acidic
pKa2	9.79	acidic
pKa3	11.6	acidic
pKa4	8.6	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	8431806	April 22, 2025	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	7850990	Jan. 23, 2027	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	8022279	Sept. 14, 2027	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	8092828	April 1, 2029	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	10166184	Oct. 15, 2032	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	10835492	Oct. 15, 2032	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	10028912	Sept. 29, 2034	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	10028912	Sept. 29, 2034	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	March 30, 2024	NEW PATIENT POPULATION
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	Aug. 3, 2024	TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
100MG;44MG	VYXEOS	CELATOR PHARMS	N209401	Aug. 3, 2017	RX	POWDER	INTRAVENOUS	March 30, 2028	TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN	INHIBITOR			WOMBAT-PK	CHEMBL
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN				WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN				WOMBAT-PK
Multidrug resistance-associated protein 6	Transporter	O95255	MRP6_HUMAN				WOMBAT-PK
72 kDa type IV collagenase	Enzyme	P08253	MMP2_HUMAN		IC50	5.72	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN				WOMBAT-PK
ORF 73	Unclassified		O40947_HHV8		AC50	5.63	CHEMBL

External reference:

ID	Source
4019704	VUID
N0000147796	NUI
D01264	KEGG_DRUG
23541-50-6	SECONDARY_CAS_RN
371770-68-2	SECONDARY_CAS_RN
1364321	RXNORM
4018061	VANDF
4019704	VANDF
C0011015	UMLSCUI
CHEBI:41977	CHEBI
DM1	PDB_CHEM_ID
CHEMBL178	ChEMBL_ID
CHEMBL1563	ChEMBL_ID
CHEMBL1200475	ChEMBL_ID
D003630	MESH_DESCRIPTOR_UI
DB00694	DRUGBANK_ID
7063	IUPHAR_LIGAND_ID
2257	INN_ID
ZS7284E0ZP	UNII
30323	PUBCHEM_CID
11753	MMSL
4538	MMSL
d00205	MMSL
002662	NDDF
004821	NDDF
108790000	SNOMEDCT_US
35300007	SNOMEDCT_US
372715008	SNOMEDCT_US
65972004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Daunorubicin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9550	INJECTION	5 mg	INTRAVENOUS	NDA	21 sections
Daunorubicin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9551	INJECTION	5 mg	INTRAVENOUS	NDA	21 sections
daunorubicin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0703-5233	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	26 sections
Daunorubicin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42658-019	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	22 sections
Daunorubicin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42658-021	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	22 sections
VYXEOS	HUMAN PRESCRIPTION DRUG LABEL	2	68727-745	INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION	44 mg	INTRAVENOUS	NDA	28 sections